Abiopharma

🔍 Simson Jake (Executive)

Company: Janux Therapeutics, Inc. (JANX)

Report Date: 2026-06-11

Detailed Transactions and Holdings:

• Acquired 5,500 shares of Common Stock (Direct)
  Date: 2026-06-11 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,750.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 15,500 shares of Stock Option (right to buy) at $13.66 per share (Derivative)
  Date: 2026-06-11 | Code: A | Expires: 2036-06-10 | equity_swap_involved: 0 | shares_owned_after: 15,500.00 | transaction_form_type: 4 | Footnotes: F3, F2

Footnotes:

• F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
• F2: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option and RSUs reported for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.
• F3: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.